Editas Medicine Inc - Understand $edit stock

$EDIT Market Cap: $320 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$67.03M

TTM

Gross Margin

Net Earnings

-$193.5M

TTM

Current Assets

$286.4M

Q2 2024

Current Liabilities

$74.31M

Q2 2024

Current Ratio

385.37%

Q2 2024

Total Assets

$384.8M

Q2 2024

Total Liabilities

$152.8M

Q2 2024

Book Value

$232.0M

Q2 2024

Cash

$64.44M

Q2 2024

P/E

-1.654

Sep 18, 2024 EST

Free Cash Flow

-$171.5M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$78.12M	$19.71M	$25.54M	$90.73M	$20.53M	$31.94M	$13.73M	$6.050M	$1.630M	$0.00	$0.00
YoY Change	296.32%	-22.83%	-71.85%	341.93%	-35.71%	132.64%	126.91%	271.17%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$78.12M	$19.71M	$25.54M	$90.73M	$20.53M	$31.94M	$13.73M	$6.050M	$1.630M	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$69.65M	$70.70M	$76.18M	$67.58M	$64.56M	$55.01M	$50.50M	$46.26M	$18.10M	$7.650M	$1.210M
YoY Change	-1.49%	-7.19%	12.73%	4.68%	17.36%	8.93%	9.17%	155.58%	136.6%	532.23%
% of Gross Profit
Research & Development	$177.7M	$175.0M	$142.5M	$158.0M	$96.90M	$90.65M	$83.16M	$56.98M	$18.85M	$5.070M	$530.0K
YoY Change	1.54%	22.77%	-9.8%	63.05%	6.89%	9.01%	45.94%	202.28%	271.79%	856.6%
% of Gross Profit
Depreciation & Amortization	$6.100M	$6.300M	$5.100M	$4.000M	$2.800M	$3.300M	$2.700M	$1.200M	$470.0K	$160.0K	$0.00
YoY Change	-3.17%	23.53%	27.5%	42.86%	-15.15%	22.22%	125.0%	155.32%	193.75%
% of Gross Profit
Operating Expenses	$247.3M	$245.7M	$218.7M	$225.6M	$161.5M	$145.7M	$133.7M	$103.2M	$36.94M	$12.72M	$1.740M
YoY Change	0.67%	12.33%	-3.05%	39.71%	10.84%	8.98%	29.47%	179.48%	190.41%	631.03%
Operating Profit	-$169.2M	-$226.0M	-$193.1M	-$134.8M	-$140.9M	-$113.7M	-$119.9M
YoY Change	-25.12%	16.98%	43.24%	-4.32%	23.91%	-5.17%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense	$17.57M	$4.225M	$2.342M	$2.610M	$7.310M	$3.450M	-$980.0K	$60.00K	-$140.0K	-$30.00K	$0.00
YoY Change	315.76%	80.4%	-10.27%	-64.3%	111.88%	-452.04%	-1733.33%	-142.86%	366.67%
% of Operating Profit
Other Income/Expense, Net	$15.96M	$5.518M	$644.0K	$18.86M	$7.176M	$3.773M	-$391.0K	-$60.00K	-$37.45M	-$930.0K	-$20.00K
YoY Change	189.27%	756.83%	-96.59%	162.88%	90.19%	-1064.96%	551.67%	-99.84%	3926.88%	4550.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	-$153.2M	-$220.4M	-$192.5M	-$116.0M	-$133.8M	-$110.0M	-$120.3M	-$97.18M	-$72.90M	-$13.69M	-$1.760M
YoY Change	-30.49%	14.51%	65.98%	-13.29%	21.65%	-8.62%	23.81%	33.31%	432.51%	677.84%
Income Tax	$0.00	$0.00	$0.00				$0.00
% Of Pretax Income
Net Earnings	-$153.2M	-$220.4M	-$192.5M	-$116.0M	-$133.7M	-$110.0M	-$120.3M	-$97.18M	-$72.90M	-$13.69M	-$1.760M
YoY Change	-30.49%	14.51%	65.98%	-13.29%	21.64%	-8.62%	23.82%	33.31%	432.51%	677.84%
Net Earnings / Revenue	-196.13%	-1118.26%	-753.61%	-127.82%	-651.43%	-344.28%	-876.49%	-1606.28%	-4472.39%
Basic Earnings Per Share	-$2.02	-$3.21	-$2.85	-$1.98	-$2.68
Diluted Earnings Per Share	-$2.02	-$3.21	-$2.83	-$1.98	-$2.68	-$2.334M	-$2.984M	-$3.016M	-$2.042M	-$383.5K	-$49.30K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$323.1M	$344.3M	$499.8M	$402.1M	$457.1M	$369.0M	$329.1M	$185.3M	$143.2M	$10.60M	$2.000M
YoY Change	-6.15%	-31.12%	24.31%	-12.03%	23.88%	12.12%	77.6%	29.4%	1250.94%	430.0%
Cash & Equivalents	$123.7M	$141.5M	$203.5M	$139.7M	$238.2M	$134.8M	$146.6M	$185.3M	$143.2M	$10.60M	$2.000M
Short-Term Investments	$199.5M	$202.8M	$296.3M	$262.4M	$219.0M	$234.2M	$182.5M
Other Short-Term Assets	$7.531M	$7.335M	$7.198M	$10.90M	$6.300M	$5.800M	$2.400M	$1.800M	$800.0K	$100.0K	$100.0K
YoY Change	2.67%	1.9%	-33.96%	73.02%	8.62%	141.67%	33.33%	125.0%	700.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$10.19M	$5.145M	$267.0K	$6.000M	$400.0K	$0.00	$700.0K	$100.0K	$1.000M	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$340.8M	$356.8M	$507.3M	$419.1M	$463.8M	$374.8M	$332.2M	$187.2M	$145.0M	$10.70M	$2.100M
YoY Change	-4.46%	-29.68%	21.05%	-9.64%	23.75%	12.82%	77.46%	29.1%	1255.14%	409.52%
Property, Plant & Equipment	$45.71M	$59.22M	$43.29M	$39.10M	$39.60M	$40.20M	$39.40M	$40.40M	$2.100M	$1.100M	$100.0K
YoY Change	-22.81%	36.79%	10.72%	-1.26%	-1.49%	2.03%	-2.48%	1823.81%	90.91%	1000.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$104.0M	$93.10M	$120.1M	$109.7M
YoY Change	11.74%	-22.47%	9.45%
Other Assets	$8.588M	$5.253M	$6.811M	$4.700M	$5.400M	$5.400M	$1.600M	$1.600M	$2.200M	$400.0K	$300.0K
YoY Change	63.49%	-22.87%	44.91%	-12.96%	0.0%	237.5%	0.0%	-27.27%	450.0%	33.33%
Total Long-Term Assets	$158.3M	$157.6M	$170.2M	$153.5M	$45.10M	$45.60M	$41.10M	$42.00M	$4.400M	$1.500M	$400.0K
YoY Change	0.48%	-7.41%	10.86%	240.35%	-1.1%	10.95%	-2.14%	854.55%	193.33%	275.0%
Total Assets	$499.2M	$514.3M	$677.5M	$572.6M	$508.9M	$420.4M	$373.3M	$229.2M	$149.4M	$12.20M	$2.500M
YoY Change
Accounts Payable	$8.269M	$9.511M	$5.050M	$6.400M	$5.800M	$5.300M	$4.000M	$4.600M	$1.400M	$2.600M	$400.0K
YoY Change	-13.06%	88.34%	-21.09%	10.34%	9.43%	32.5%	-13.04%	228.57%	-46.15%	550.0%
Accrued Expenses	$46.73M	$42.38M	$30.50M	$30.90M	$27.90M	$12.80M	$11.00M	$17.40M	$5.500M	$1.600M	$700.0K
YoY Change	10.26%	38.94%	-1.29%	10.75%	117.97%	16.36%	-36.78%	216.36%	243.75%	128.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$7.500M	$10.00M	$0.00	$0.00	$0.00
YoY Change						-100.0%	-25.0%
Long-Term Debt Due									$0.00	$100.0K	$0.00
YoY Change									-100.0%
Total Short-Term Liabilities	$63.22M	$60.11M	$46.88M	$58.20M	$60.00M	$35.90M	$36.70M	$33.10M	$6.900M	$6.200M	$2.100M
YoY Change	5.17%	28.21%	-19.44%	-3.0%	67.13%	-2.18%	10.88%	379.71%	11.29%	195.24%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$32.40M	$33.40M	$35.10M	$0.00	$300.0K	$0.00
YoY Change					-100.0%	-2.99%	-4.84%		-100.0%
Other Long-Term Liabilities	$86.84M	$93.53M	$76.96M	$120.8M	$186.5M	$115.9M	$95.00M	$26.40M	$25.60M	$200.0K	$0.00
YoY Change	-7.15%	21.54%	-36.29%	-35.23%	60.91%	22.0%	259.85%	3.13%	12700.0%
Total Long-Term Liabilities	$86.84M	$93.53M	$76.96M	$120.8M	$186.5M	$148.3M	$128.4M	$61.50M	$25.60M	$500.0K	$0.00
YoY Change	-7.15%	21.54%	-36.29%	-35.23%	25.76%	15.5%	108.78%	140.23%	5020.0%
Total Liabilities	$150.1M	$153.6M	$123.8M	$179.0M	$246.4M	$184.2M	$165.2M	$94.60M	$32.60M	$6.700M	$2.100M
YoY Change	-2.33%	24.06%	-30.82%	-27.35%	33.77%	11.5%	74.63%	190.18%	386.57%	219.05%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	75.97M shares	68.66M	67.62M	58.61M	49.98M
Diluted Shares Outstanding	75.97M shares	68.66M	67.62M	58.61M	49.98M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $320.01 Million

About Editas Medicine Inc

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 265 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Industry: Biological Products, (No Diagnostic Substances) Peers: TG Therapeutics Inc CareDx Inc Design Therapeutics Inc Geron Corp Rocket Pharmaceuticals Inc Keros Therapeutics Inc Kura Oncology Inc Nuvalent Inc POINT Biopharma Global Inc.